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cedures are 81% (95% CI: 73%-89%; p< 0.0001) more likely to suffer an anastomotic 
leak than laparoscopic procedures. ConClusions: In colorectal resections, anasto-
motic leaks are associated with a longer LOS, an increased likelihood of readmission 
during the 30-day post-operative period and an incremental economic burden of 
$13,797 per patient during the index hospitalization.
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objeCtives: The objective of this study was to determine the health care burden 
associated with breast cancer in the Medicaid population in terms of health care 
use and costs associated with the condition. Methods: This study used the 2006-
2008 Medicaid analytic extract files for 39 states in the United States. The target 
population included recipients aged 18-64 years who were continuously enrolled 
in Medicaid during 2006-2008. Breast cancer-related health care utilization during 
2007-2008 in terms of inpatient, outpatient, and emergency room visits and treat-
ment use was determined for women with breast cancer. The excess health care 
burden attributable to breast cancer during 2007-2008 was determined by comparing 
all-cause health care use and costs between Medicaid recipients with breast cancer 
and a matched control group of recipients without breast cancer. Generalized linear 
model with log link and Poisson distribution was used for multivariable comparison 
of all-cause costs between recipients with and without breast cancer. Results: We 
identified 34,198 cases of breast cancer in the Medicaid population. Breast cancer-
related inpatient, outpatient, and emergency room visits were higher among women 
aged 30-39 and 40-49 years and ethnic minorities as compared to women aged 18-29, 
50-59, and 60-64 years and whites respectively (p< 0.0001). Hormonal therapy was 
the most commonly used treatment (26.8% and 28.1% of the recipients in 2007 and 
2008 respectively). The all-cause inpatient, outpatient, and emergency room visits 
were higher in recipients with breast cancer as compared to those without breast 
cancer (p< 0.0001). In the multivariable analysis, recipients with breast cancer were 
found to have ~23.4% higher costs per year as compared to recipients without breast 
cancer (estimate: 0.2104, 95% confidence interval: 0.1955–0.2252). ConClusions: 
Breast cancer is associated with a considerable health care burden in the Medicaid 
population. Health care use and costs were considerably greater among recipients 
with breast cancer as compared to those without breast cancer.
PCN62
Cost Profile of PatieNts witH GastriC CaNCer usiNG uNited states 
adMiNistrative ClaiMs data
Hirst C.1, Ryan J.1, Tunceli O.2, Wu B.2, Kern D.M.2
1AstraZeneca, Macclesfield, UK, 2HealthCore, Inc., Wilmington, DE, USA
objeCtives: Gastric cancer (GC) is the fourth most common cancer globally and 
an important cause of morbidity and mortality in the US. Prognosis is poor, treat-
ment options are limited, and there has been little progress in improving outcomes 
over the last 25 years. The objective of the study was to describe the demographic 
and clinical characteristics, mortality, health care utilization and cost of patients 
with gastric cancer. Methods: A retrospective cohort study on GC and non-cancer 
patients was conducted using the HealthCore Integrated Research Environment dur-
ing 2007-2012. GC cases were ≥ 18 years, had at least 2 diagnosis codes for GC within 
60 days (first diagnosis was index) and had 12 months pre-index history. GC patients 
were matched 1-to-10 with patients having no diagnosed cancer on age, gender, 
health plan type, and geographic region. Descriptive analyses were performed for 
health care utilization and cost, and mortality. Stratified analyses were conducted by 
patient age, site of cancer and coding for metastatic disease. Results: There were 
1,668 GC cases and 16,680 cancer free patients. Mean age was 66 years and 65% of 
patients were male. Patients with GC incurred more than ten times the health care 
costs than those without cancer ($96,571 vs. $8,338) during the follow-up period, 
particularly those with advanced disease ($131,663). When including only those 
costs specifically linked to gastric cancer, these differences remain. Three-year sur-
vival was 45% and 94% in patients with GC and without cancer, respectively (hazard 
ratio= 14.9). Chemotherapy and/or chemo-radiation without curative surgery was 
the most common treatment seen in GC patients during the first 18 months of fol-
low-up (53%); trastuzumab use was only detected in 17 patients. ConClusions: GC 
represents a significant burden both to the individual and health care system, with 
considerably higher resource use and costs than matched patients without cancer.
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objeCtives: To estimate the 1-year burden following TKI treatment failure of first-
line (1L) imatinib or first/second/third-line (1L/2L/3L) dasatinib or nilotinib in CML 
from a US managed care perspective. Methods: Treatment episodes initiating 
a TKI of interest (index TKI) during 6/2008-12/2011 were identified from the IMS 
PharMetrics Plus Health Plan Claims Database for adult patients with CML diagnosis 
(ICD-9-CM 205.1x), 120-days pre-index continuous enrollment (CE) and no clinical 
trial participation. Episodes experiencing treatment failure, defined as switch to a 
non-index TKI or discontinuation of index TKI (gap of ≥ 60 days), and with 1-year CE 
post-failure, were analyzed. LOT was determined by number of unique TKIs used 
pre-index (1L:0, 2L:1, 3L:2). All-cause medical resource utilization (MRU) and costs 
(2012 USD) in the 1-year post-failure were assessed by LOT. Adjusted relative rates 
(RR) for mean MRU and costs for 2L vs. 1L were estimated via generalized linear 
models. Results: 706 episodes (1L:518, 2L:180, 3L:8) were identified (mean age= 53 
region. Determinants of the difference in total costs include hospital expense and 
drug price. ConClusions: In a large, randomized trial in RCC, patients receiving 
pazopanib were less expensive compared to patients receiving sunitinib.
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objeCtives: Androgen ablation (ADT) maintenance is recommended during castra-
tion-resistant prostate cancer; however the overall cost of medications during this 
phase is dramatically increasing with ADT accounting for almost 21% of the total 
cost. The objective of this study was to perform a cost comparison of different forms 
of ADT, including luteinizing hormone releasing hormone agonists (LHRHa) medi-
cations and surgical castration, over the phase of metastatic castration-resistant 
prostate cancer (mCRPC). Methods: Two Markov models were developed in order 
to simulate survival in mCRPC, and the cost of ADT as per Quebec’s public health 
care system. The models include recently approved additional lines of treatment 
after and/or before docetaxel (i.e. abiraterone and cabazitaxel). Survival was based 
on clinical trial results and clinical practice guidelines found in a literature review. 
Costs are in Canadian dollars ($). Results: The mean cost of ADT per patient in 
mCRPC over an average period of 28.1 months was estimated at: $1,413 for surgical 
castration, $8,346 for Leuprolide (Eligard), $8,514 for Triptorelin (Trelstar), $9,891 
for Buserelin (Suprefact Depot), $10,032 Leuprolide (Lupron Depot), and $10,172 for 
Goserelin (Zoladex). The corresponding values obtained with the alternate model 
(which includes abiraterone initiation prior to docetaxel therapy) over a 37.2 months 
were: $1,413, $11,078, $11,302, $13,130, $13,316 and $13,503, respectively. For each 
annual Canadian cohort of 4,000 mCRPC patients, for a 28.1 months period, the 
total cost of ADT was estimated at $ 5.6 million for surgical castration, and between 
$33.4 and $40.7 million for LHRHa therapy. For a 37.2 months period, the total cost 
for surgical castration remained the same and was between $44.3 and $54.0 million 
for LHRHa therapy. ConClusions: Our study estimates the costs associated with 
the use of different ADT in mCRPC. Increasing the use of least costly forms of ADT 
will result in potential cost savings during the mCRPC phase.
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objeCtives: The direct medical costs of melanoma patients by disease stage have 
not been well reported. This study used Surveillance, Epidemiology, and End Results 
(SEER) – Medicare linked data to examine costs in patients with melanoma, by 
disease stage. Methods: All patients diagnosed with stage IIIB, IIIC, M1a, M1b, 
or M1c melanoma in SEER-Medicare data 2004 - 2009 were included in the study. 
Follow up period was ≥ 1 month, starting from the date of the first diagnosis of 
stage IIIB-M1c melanoma until death or end of the study period. All-cause medical 
costs were standardized as per patient per month (PPPM) and adjusted to 2013 dol-
lars. Results: A total of 1263 melanoma patients met the study criteria, with 43.5% 
at Stage IIIB, 23.0% IIIC, 11.6% M1a, 8.9% M1b, and 12.9% M1c. Their mean age was 
75.0 (standard deviation (SD) 9.3), 65.3% was male, and mean follow up length was 
37.5 (SD 22.7) months. The mean PPPM costs were $1851 (SD $2168) for patients with 
Stage IIIB, $2557 (SD $2759) for Stage IIIC, $2278 (SD $2722) for Stage M1a, $3203 (SD 
$3582) for Stage M1b, and $4317 (SD $3910) for Stage M1c. Across all disease stages, 
outpatient and inpatients costs were the primary cost drivers, outpatient costs 
accounting for 37.5% (for patients at Stage M1c) to 47.7% (for patients at Stage IIIB), 
while inpatient costs accounting for 36.1% (M1b) to 40.9% (M1c) of the total medi-
cal costs. The other cost categories were hospice stay (6.3% - 16.5% of total medical 
costs), skilled nursing facility (2.8% - 7.8%), home health care (0.9% - 1.6%), and emer-
gency room visits (0.9% – 1.2%). ConClusions: Patients at later stages had higher 
total medical costs than patients at earlier stages. Treatments that prevent or delay 
disease progression to later stages could potentially reduce total medical costs.
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objeCtives: Anastomotic leaks following colorectal resections result in increased 
morbidity, mortality, and costs. These types of surgeries are performed via an open 
or laparoscopic approach. This analysis compares the total health care utilization 
and reimbursement by comparing colorectal resections with and without anas-
tomotic leak complications. Methods: This study utilized administrative health 
claims data from MarketScan® Commercial and Medicare databases from January 
2009 to December 2011. Patients undergoing colorectal resections with an anasto-
mosis were identified from ICD-9 procedure codes. An algorithm based on clinical 
expertise was developed which utilized relevant ICD-9 diagnosis codes to identify 
patients with suspected anastomotic leaks. A multivariate logistic regression analy-
sis for the binary outcome of anastomotic leak (yes or no) was performed analyzing 
length of stay (LOS), rehospitalization, and reimbursement. Reimbursement and 
LOS were modeled with generalized linear models with a gamma distribution and 
log-link. Results: A total of 78,622 colorectal resections were identified, including 
73,945 with a colorectal resection primary code (94.1%) and 4,677 with an anastomo-
sis primary code and secondary resection code (5.9%). Procedures with anastomotic 
leaks are associated with longer LOS than without anastomotic leaks (9.5 versus 
6.2 days; p< 0.0001) and are 124% (95% CI, 111% to 137%; p< 0.0001) more likely to 
be readmitted within 30 days. Health care expenditures during the index inpatient 
stay for patients with anastomotic leaks are higher than for those without ($43,792 
versus $29,995; p< 0.0001). Multivariable logistic regression showed that open pro-
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and common comorbid conditions included diabetes (27.3%), tumor (23.6%) and 
moderate or severe renal disease (21.2%). Simvastatin (7.3%), lisinopril (5.9%) and 
hydrocodone bitartrate/acetaminophen (5.1%) were the most frequently prescribed 
medications. During the follow-up period, PC patients had evidence of the follow-
ing health care utilizations: Medicare carrier (98.0%), Durable Medical Equipment 
(DME, 32.1%), Home Health Agency (HHA, 12.1%), outpatient visits (75.9%) and inpa-
tient hospital (29.5%), Skilled Nursing Facility (SNF, 7.2%) and hospice admissions 
(5.4%) and prescription drug (part D event) claims (43.7%). PC patients incurred 
higher Medicare carrier ($6,330), DME ($328), HHA ($647), outpatient ($19,041), 
inpatient ($5,814), SNF ($1,229), hospice ($475), pharmacy ($1,144) and total costs 
($35,008). ConClusions: Patients who were enrolled in Medicare and diagnosed 
with PC had high utilization of Carrier and outpatient services, as well as frequent 
comorbid conditions, resulting in considerable health care expenditures.
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objeCtives: In previous studies in chronic lymphocytic leukemia (CLL), adverse 
events (AEs) associated with commonly used therapies have primarily consisted 
of infusion reaction, myelotoxicity, and infection. This study estimated the cost of 
specific AEs per course of therapy associated with commonly used first-line treat-
ment regimens for CLL in the United States. Methods: This retrospective claims 
data analysis used Truven Health Analytics MarketScan® commercial and supple-
mental Medicare databases from January 2005 through August 2012. Eligible patients 
were ≥ 18 years, had a diagnosis of CLL, and continuous enrollment for ≥ 6 months 
prior to diagnosis. All patients received ≥ 1 dose of one of the following 5 regimens: 
fludarabine, cyclophosphamide, and rituximab (FCR); bendamustine plus rituximab 
(BR); chlorambucil, fludarabine plus rituximab (FR); or rituximab. AEs were identified 
from ICD-9-CM codes that either explicitly described the event of interest or that 
described interventions that were specific to the AE. Costs related to each AE were 
summed from diagnosis to the end of initial therapy. Drug costs of CLL therapies 
were excluded. Adjusted costs were estimated using a propensity-weighted general-
ized linear model (GLM), which controlled for differences in baseline characteristics 
across treatment groups. Results: Of 2,035 patients, 497 received FCR, 130 received 
BR, 449 received chlorambucil, 297 received FR, and 662 received rituximab. Mean 
age was 69.5 years (SD: 12.4) and 64% were male. Comorbidities included diabetes 
(19%), COPD (16%), and cardiovascular (14%) disease. AE results (frequency; adjusted 
cost; and 95% CI, respectively) were as follows: infusion reaction (40%; $4482; $4141-
$4862), anemia (35%; $8894; $8267-$9586), infection (26%; $7163; $6648-$7733), dysp-
nea (9%; $859; $751-$989), neutropenia (8%; $5406; $4629-$6367), febrile neutropenia 
(5%; $17,274; $14,374-$21,010), thrombocytopenia (2%; $12,621; $8933-$18,651), and 
leukopenia (1%; $1720; $1218-$2539). ConClusions: Infusion reaction, myelotoxic-
ity, and infection have substantial economic costs in CLL, which may be reduced by 
improved patient management.
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objeCtives: To collect health care resource utilization (HCRU) in the manage-
ment of chronic lymphocytic leukemia (CLL) patients who have relapsed/refrac-
tory disease, and had at least one previous chemotherapy treatment. Methods: 
A retrospective, longitudinal, cohort study design is being used involving three 
cancer centres in Ontario, Canada. A convenience sample of 90 CLL patients was 
selected with inclusion criteria of adult age at diagnosis, date of diagnosis between 
January 1, 2006 to 2012, relapsed/refractory disease that required at least one previ-
ous therapy, and minimum of one oncology visit. Demographics and HCRU data were 
collected with descriptive statistics to be presented. Costs are in 2013 Canadian dol-
lars. Results: At the Juravinski Cancer Centre (Hamilton, Ontario), 30 CLL patients 
met the study inclusion criteria. 22 were male with the mean age at diagnosis being 
65.2 years (range 41-86 years). 43% (13/30) of the interim cohort had genetic test-
ing. 73.3% of patients (22/30) received fludarabine-based chemotherapy as first-line 
treatment. 13.6% (3/22) were re-treated with fludarabine as second-line treatment. 
26.7% of patients (8/30) received chlorambucil as first-line treatment. Of those, 2 
patients were re-treated with chlorambucil as second-line treatment, 4 received 
fludarabine-based chemotherapy, and 2 did not receive further treatment. 40% of 
patients (12/30) were given rituximab. 90% of patients who needed other medica-
tions utilized a mean number of 6.0 (0-15) drugs. Half of the cohort visited the emer-
gency department a total of 19 times and experienced 25 adverse events. The total 
cost of diagnostic tests/procedures was $17,502, $28,895 for hospitalizations, and 
$49,794 for specialist visits. ConClusions: Preliminary results from one cancer 
centre indicate substantial HCRU associated with CLL management. The authors 
plan to complete data extraction at the two remaining cancer centres in order to 
determine HCRU and cost results for the full cohort.
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years, 51% female, 97% commercially-insured). Unadjusted 1-year post-failure costs 
increased by LOT for total health care (1L:$78,667, 2L:$99,624, 3L:$181,029) and medi-
cal services (i.e., non-pharmacy) (1L:$35,578, 2L:$51,078, 3L:$146,768), as did medical 
costs as a proportion of total costs (1L:45%, 2L:51%, 3L:81%). In adjusted analyses, 
compared to 1L, 2L failures had: 45% more ambulatory visits (mean 31 vs. 21, 95% CI 
on RR 1.26-1.66), 75% higher risk of hospitalization (33% vs. 23% hospitalized, 95% 
CI 1.16-2.64), 38% higher total costs (95% CI 1.14-1.68), and 73% higher medical costs 
(95% CI 1.31-2.29). Medical costs comprised a greater proportion of total costs in 2L 
vs. 1L (55% vs. 44%); pharmacy costs did not increase significantly. ConClusions: 
The burden of TKI treatment failure increases by LOT, due to increased MRU and 
associated costs. More efficacious treatment used in early therapy lines may reduce 
downstream costs by preventing treatment failure.
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objeCtives: In recent years, breast cancer remains the leading cause of death 
in women worldwide. Evaluating the economic burden of breast cancer is very 
important due to long-term treatment with expensive drugs and medical services. 
In Vietnam related studies has not been conducted until now. This is also the aim of 
this study. Methods: The cost of breast cancer has been evaluated using pharma-
coeconomic method “cost of illness” by following formula: COI = DC + IC in which: 
COI - cost of illness, DC- direct cost, IC- indirect cost A tree-decision model has been 
developed to evaluate the cost of different stages of breast cancer. This analysis was 
conducted based on the perspective of health insurance companies, therefore only 
direct medical costs were evaluated. The price of drugs and medical services have 
been averaged from the price-list of some major hospitals in Vietnam. The cost of 
disease for the whole society of Vietnam has been evaluated based on epidemiologi-
cal data in Vietnam in 2013. Results: The average cost of treatment per year of 
breast cancer in stage 0- I, II, III, IV accounts for 33,166,886; 287,057,068; 325,116,474 
and 153,352,776 VND, respectively. In the structure of average cost with the increas-
ing in severity of disease, the percentage of drug costs increase (from 28.7% in stage 
0-I to 95.1% in stage 4) and the percentage of medical services decrease (from 71.3% 
in stage 0-I to 4.9% in stage 4). The cost of breast cancer for the whole society of 
Vietnam resulted in around 6,633 billion VND. ConClusions: The cost of breast 
cancer increases following the severity level of disease with the increasing percent-
age of drugs costs and reducing percentage medical services costs. The high cost of 
breast cancer for the whole society of Vietnam needs to be concerned to conduct 
the relevant health care policies.
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objeCtives: Evaluate the economic burden of non-small cell lung cancer (NSCLC) 
in Vietnam. Methods: Economic burden analysis has been conducted, following 
which the economic burden of NSCLC for the whole society of Vietnam has been 
evaluated by following formulas: C = ∑Pi x COIi in which, C: economic burden of 
NSCLC in Vietnam; Pi: number of patients in stage i of NSCLC in Vietnam, COIi: cost 
of NSCLC in stage i The analysis has been conducted based on the perspective of 
health insurance companies, therefore only medical direct cost has been evaluated. 
The cost of drugs and medical services has been averaged from the relevant drugs 
and medical services of some major hospitals in Vietnam. The number of patients in 
every stage of NSCLC has been retrieved from epidemiological database of Vietnam in 
2010. The model has been developed to evaluate the economic burden of NSCLC and 
also further adapt the changes of price and epidemiological data over years. Results: 
The economic burden of NSCLC for the whole society of Vietnam is over 3,517 billion 
VND. In the structure of economic burden of NSCLC, the economic burden for drugs 
consists of 73.9% (2,600 billion VND), which is around 3 times higher than economic 
burden for medical services (900 billion VND). Comparing the economic burden of 
NSCLC by stages, it has been found that the economic burden of NSCLC increases 
with the increasing in the severity of disease. However stage III with the less severity 
than stage IV has the highest economic burden with the amount of 2,490 billion VND 
due to the high cost of treatment and high number of patients. ConClusions: The 
high economic burden of NCSLC should be considered to conduct the relevant health 
care policies, especially with high-cost drugs and patients in late stages of disease.
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objeCtives: To examine the economic burden and health care utilizations of U.S. 
Medicare patients diagnosed with prostate cancer (PC). Methods: A retrospec-
tive analysis was conducted using national Medicare claims data (01JAN2008-
31DEC2010). Medicare beneficiaries diagnosed with PC were identified using 
International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) 
diagnosis code 185.xx, and the initial diagnosis date designated as the index date. 
Eligible patients were required to have 1 year continuous enrollment pre- and post-
index date. Charlson Comorbidity Index (CCI) score and baseline comorbid condi-
tions were examined for the baseline period. Prescribed medications were captured 
within 60 days post-index date. Health care utilization and costs were measured 
for the follow-up period, and costs were adjusted to 2010 U.S. dollars. Results: 
A total of 21,616 PC patients were identified, of which 99.2% were male and 84.4% 
Caucasian. PC patients enrolled in Medicare had a mean age at 76.1 years and more 
often resided in the Southern U.S. region (37.7%). The baseline CCI score was 1.76, 
